Relevance of in vitro neurotoxicity testing for regulatory requirements: Challenges to be considered

被引:69
|
作者
Bal-Price, Anna K. [1 ]
Hogberg, Helena T. [1 ]
Buzanska, Leonora [1 ,2 ]
Coecke, Sandra [1 ]
机构
[1] Commiss European Communities, Joint Res Ctr, European Ctr Validat Alternat Methods, Inst Hlth & Consumer Protect,In Vitro Toxicol Uni, I-21020 Ispra, VA, Italy
[2] Polish Acad Sci, Med Res Ctr, NeuroRepair Dept, Warsaw, Poland
关键词
In vitro neurotoxicity testing; Models; Endpoints; Metabolism; New technologies; EMBRYONIC STEM-CELLS; NEURAL PROGENITOR CELLS; UMBILICAL-CORD BLOOD; DEVELOPMENTAL NEUROTOXICITY; NEURITE OUTGROWTH; DIFFERENTIATION; TOXICITY; METABOLISM; LINE; RECOMMENDATIONS;
D O I
10.1016/j.ntt.2008.12.003
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The current testing requirements for both adult and developmental neurotoxicity evaluation are based on in vivo animal models and the neurotoxic potency of compounds is mainly determined by neurobehavioural and neuropathological effects. In vitro studies are considered complementary to animal tests because they provide an understanding of the molecular/cellular mechanisms involved in neurotoxicity. However, the selection of relevant in vitro neuronal/glial specific endpoints applied to various neuronal cellular models should be done in a careful way to build reliable and feasible testing strategies since usually these endpoints have to be tested in various complementary in vitro systems. The requirements for applying a more complex test strategy where toxicokinetic aspects are included together with different tools to compensate for the lack of in vitro metabolic competence are discussed. Taking into consideration the recent European Commission chemical legislation concerning registration, evaluation and authorisation of chemicals (REACH) it has become a priority to develop new intelligent testing strategies integrating computational models and in vitro assays based on cell culture models and endpoints that are amenable for adaptation to high throughput screening to be able to test a large number of chemicals. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:36 / 41
页数:6
相关论文
共 50 条
  • [31] Analytical challenges and developments for methods required to support regulatory requirements
    Martos, Perry
    Wroblewski, Charles
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [32] Nitrosamines impurities carcinogenicity assessment - regulatory requirements, challenges and recommendations
    Mishra, S.
    Autiero, M.
    Vishnoi, S.
    De Roy, C.
    Barai, N.
    Chakraborty, S.
    Tencalla, F.
    Petry, T.
    TOXICOLOGY LETTERS, 2023, 384 : S280 - S281
  • [33] NEW REGULATORY REQUIREMENTS IN 2012: CHALLENGES OF PIPELINE REGULATORY COMPLIANCE AND THE TOOLS TO MEET THEM
    Flo, Daniel S.
    Walker, Rachel E.
    Fasking, Todd M.
    PROCEEDINGS OF THE 9TH INTERNATIONAL PIPELINE CONFERENCE - 2012, VOL 1, 2013, : 301 - 305
  • [34] United States regulatory requirements for skin and eye irritation testing
    Choksi, Neepa Y.
    Truax, James
    Layton, Adrienne
    Matheson, Joanna
    Mattie, David
    Varney, Timothy
    Tao, Jenny
    Yozzo, Krystle
    McDougal, Andrew J.
    Merrill, Jill
    Lowther, Donnie
    Barroso, Joao
    Linke, Brenda
    Casey, Warren
    Allen, David
    CUTANEOUS AND OCULAR TOXICOLOGY, 2019, 38 (02) : 141 - 155
  • [35] Safety enhancement considered pn the development of safety and regulatory requirements for the Korean next generation reactor
    Lee, JH
    Seul, KW
    Yune, YG
    Kim, WS
    Chung, YH
    Ko, CS
    Ahn, HJ
    Yoon, WH
    PROCEEDINGS OF THE INTERNATIONAL TOPICAL MEETING ON ADVANCED REACTORS SAFETY, VOLS 1 AND 2, 1997, : 321 - 328
  • [36] Has in vitro allergenicity testing any clinical relevance?
    Vandenplas, Y
    Hauser, B
    ALLERGY, 2002, 57 (02) : 73 - 75
  • [37] Developmental Neurotoxicity - Challenges in the 21st Century and In Vitro Opportunities
    Smirnova, Lena
    Hogberg, Helena T.
    Leist, Marcel
    Hartung, Thomas
    ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION, 2014, 31 (02) : 129 - 156
  • [38] Toward a Better Testing Paradigm for Developmental Neurotoxicity: OECD Efforts and Regulatory Considerations
    Sachana, Magdalini
    Shafer, Timothy J.
    Terron, Andrea
    BIOLOGY-BASEL, 2021, 10 (02): : 1 - 11
  • [39] Assessment of neurotransmitter release in human iPSC-derived neuronal/glial cells: a missing in vitro assay for regulatory developmental neurotoxicity testing
    Cervetto, Chiara
    Pistollato, Francesca
    Amato, Sarah
    Mendoza-de Gyves, Emilio
    Bal-Price, Anna
    Maura, Guido
    Marcoli, Manuela
    REPRODUCTIVE TOXICOLOGY, 2023, 117
  • [40] Key Challenges and Recommendations for In Vitro Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure Parameters
    Moore, Martha M.
    Abraham, Irene
    Ballantyne, Mark
    Behrsing, Holger
    Cao, Xuefei
    Clements, Julie
    Gaca, Marianna
    Gillman, Gene
    Hashizume, Tsuneo
    Heflich, Robert H.
    Hurtado, Sara
    Jordan, Kristen G.
    Leverette, Robert
    McHugh, Damian
    Miller-Holt, Jacqueline
    Phillips, Gary
    Recio, Leslie
    Roy, Shambhu
    Scian, Mariano
    Simms, Liam
    Smart, Daniel J.
    Stankowski, Leon F., Jr.
    Tarran, Robert
    Thorne, David
    Weber, Elisabeth
    Wieczorek, Roman
    Yoshino, Kei
    Curren, Rodger
    ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2023, 51 (01): : 55 - 79